A central finding from our study is that the presence of pre-existing immunity (higher expression of specific immune-related signatures, and intra-tumoral CD8+ T cell density) in baseline tumor tissues was associated with better clinical outcomes with this triple combination. This evidence concerns the gene CD8A and neoplasm.